| Oct 1 |
Evoke Pharma announces proceeds from existing warrants and board expansion
|
| Oct 1 |
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
|
| Sep 19 |
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
|
| Sep 9 |
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
|
| Sep 4 |
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
|
| Aug 29 |
Evoke Pharma files for $50M mixed securities shelf
|
| Aug 15 |
Evoke Pharma Second Quarter 2024 Earnings: Misses Expectations
|
| Aug 13 |
Evoke Pharma files for mixed shelf offering
|
| Aug 13 |
Evoke Pharma GAAP EPS of -$0.93, revenue of $2.55M
|
| Aug 13 |
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
|
